Multiple Myeloma
Conditions
Brief summary
The researchers want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment.
Interventions
PROCEDURETransfusion
Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
Sponsors
University of Arkansas
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with advanced hematological malignancies who have failed at least two lines of therapy. * Karnofsky performance score \> 60, unless due to disease and then \> 50. * Age \> 18 years. * An expected survival of \> 3 months. * Subjects must have signed an IRB-approved consent and been informed about the investigational nature of the study. * Cord blood must have negative serology for HIV. * Release of cord blood. * The nucleated cell count of the CBU shall equal or exceed 1 x 107 per kg of recipient body weight.
Exclusion criteria
* Liver function: total bilirubin \> 2x ULN or AST/ALT \> 3x ULN. * Creatinine \> 3.0 mg/dL.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The researchers on this study want to find out if subjects treated on this study will achieve long term bone marrow recovery (engraftment) and if their tumors will respond to this treatment. | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| The researchers also want to find out what types of side effects, if any, subjects will experience with this treatment. | 12 months |
Countries
United States
Outcome results
None listed